Beta blocker prophylaxis for patients with variceal hemorrhage

Journal of Clinical Gastroenterology

Volumn 39, Issue 5, 2005, Pages 435-440

  Wilbur, Kerry ^a,b   Sidhu, Kirhan ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Beta blocker; Liver disease; Prophylaxis; Variceal hemorrhage

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NADOLOL; NITRATE; OCTREOTIDE; PROPRANOLOL; PROTON PUMP INHIBITOR; SCLEROSING AGENT;

ADULT; CONTROLLED STUDY; ESOPHAGUS VARICES BLEEDING; FEMALE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; RISK REDUCTION;

ADRENERGIC BETA-ANTAGONISTS; ENDOSCOPY, GASTROINTESTINAL; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; LENGTH OF STAY; MALE; MIDDLE AGED; PROPRANOLOL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 17444429290     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000159222.16032.98     Document Type: Review

References (58)

1. Canadian Liver Foundation [online]. 2002 [cited 2002, November 14]. Available from: URL: http://www.liver.ca/englis/index.html.
2. Kim WR, Brown RS Jr, Terrault NR, et al. Burden of liver disease in the United States. Workshop summary of the American Association for the Study of Liver Diseases, Digestive Diseases Week, May 2001. Available from: URL: http://www.hcvadvocate.org/hepatitis/About_Hepatitis_pdf/ 1.1_Hepatits_C/Burden. pdf
3. Sharara AI, Rockey DC. Gastroesophageal variceal hemorrhage. N Engl J Med. 2001;345:669-681.
4. McCormick PA, O'Keefe C. Improving prognosis following a first variceal hemorrhage over four decades. Gut. 2001;49:682-685.
5. Hayes PC, Davis JM, Lewis JA, et al. Meta-analysis of the value of propranolol in the prevention of variceal hemorrhage. Lancet. 1990;336: 153-156.
6. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19: 475-503.
7. Teran JC, Imperiale T, Mullen KD, et al. Primary prophylaxis of variceal bleeding in cirrhosis: a cost-effectiveness analysis. Gastroenterology. 1997;112:473-482.
8. Garcia-Pagan JC, Villanueva C, Vila MC, et al. Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta blocker. Gastroenterology. 2001;121:905-914.
9. Navasa M, Chesta J, Bosch J, et al. Reduction of portal pressure by 1-5-mononitrate in patients with cirrhosis: effects on splanchnic and systemic hemodynamics and liver function. Gastroenterology. 1989;96:1110-1118.
10. Angelico M, Carli L, Piat C, et al. Effects of isosorbide-5-monnitrate compared with propranolol on first bleeding and long term survival in cirrhosis. Gastroenterology. 1997;113:1632-1639.
11. Garcia-Pagan JC, for the Spanish Variceal Bleeding Study Group. Isosorbide-5-mononitrate vs placebo in the prevention of the first variceal bleeding (FVB) in patients with contraindications or intolerance to beta-blockers. J Hepatol. 2000;2:28a.
12. Angelica M, Lionetti R. Long-acting nitrates in portal hypertension: to be or not to be? Dig Liver Dis. 2001;33:205-211.
13. Borroni G, Salerno F, Cazzaniga M, et al. Nadolol is superior to isosorbide mononitrate for the prevention of the first variceal bleeding in cirrhotic patients with ascites. J Hepatol. 2002;37:315-321.
14. Garcia-Pagan. Non-selective beta-blockers in the prevention of first variceal bleeding: is there any definite alternative? J Hepatol. 2002;37: 393-395.
15. Merkel C, Sacerdoti Bolognesi M, Enzo E, et al. Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to beta blockers. Hepatology. 1997;26:34-39.
16. Merkel C, Marin R, Sacerdoti D, et al. Long-term results of a clinical trial of nadolol with or without isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000;31:324-329.
17. Garcia-Pagan JC, Morillas R, Banares F, et al. Propranolol + placebo vs. propranolol + isosorbide-5-mononitrate in the prevention of the first variceal bleeding. Hepatology. 2003;37:1260-1266.
18. D'Amico G, Pasta L, Parti R, et al. Isosorbide mono-nitrate wity nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis: a double-blind placebo-controlled randomized trial. J Hepatol. 2002; 30:66.
19. Garcia-Pagan JC, Feu F, Bosch J, et al. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: a randomized controlled study. Ann Intern Med. 1991;114:869-873.
20. Garcia-Pagan JC, Navasa M, Bosch J, et al. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology. 1990; 11:230-238.
21. Pietrosi G, D'Amico G, Pasta L, et al. Isossorbide mononitrate (IMN) with nadolol compared to nadolol alonde for the prevention of first bleeding in cirrhosis: a double-blind placebo-controlled randomised trial. J Hepatol. 1999;66:WP3/21.
22. Gournay J, Masliah C, Martin T, et al. Isosorbide mononitrate and propranolol compared with propranolol alone for the prevention of variceal rebleeding. Hepatology. 2000;31:1239-1245.
23. Parti R, D'Amico G, Pasta L, et al. Isosorbide mononitrate (IMN) with nadolol compared to nadolol alone for prevention of recurrent bleeding in cirrhosis: a double-blind placeobo controlled randomized trial. J Hepatol. 1999;30 (Suppl):81A.
24. Jalan R, Hayes PC. UK guidelines on the management of variceal hemorrhage in cirrhotic patients. Gut. 2000;46 (Suppl III):1-15.
25. Vlachogiannakos J, Tang AK, Patch D, et al. Angiotensin converting enzyme inhibitors and angiotensin II antagonists as therapy in chronic liver disease. Gut. 2001;49:303-308.
26. Steigmann GV. Motion: prophylactic banding of esophageal varices is useful. Arguments for the motions. Can J Gastroenterol. 2002;16:689-692.
27. de Franchis R. Updating consensus in portal hypertension: Report of the Baveno III consensus workshop on definitions, methodology, and therapeutic strategies in portal hypertension. J Hepatol. 2000;33:846-852.
28. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
29. 9. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl. 2001;7:567-580.
30. ACC/AHA. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol. 1996;28:1328-1428.
31. European Society of Cardiology. European Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527-1560.
32. Sorbi D, Gostout CH, Peura D, et al. An assessment of the management of acute bleeding varices: a multicenter prospective member-based study. Am J Gastroenterol. 2003;98:2424-2434.
33. Chalsani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol. 2003; 98:653-659.
34. D'Amico G, De Franchis R, and a Cooperative Study Group. Upper digestive bleeding in cirrhosis: post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599-612.
35. D'Amico G, Luca A. Natural history: clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol. 1997;11:243-256.
36. Vlachogiannakos J, Goulis J, Patch D, et al. Review article: primary prophylaxis for portal hypertensive bleeding in cirrhosis. Aliment Pharmacol Ther. 2000;14:851-860.
37. Groszmann RG, Garcia-Tsao G, Makuch R, et al. Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of complications of portal hypertension: final results and identification of a predictive factor [Abstract]. Hepatology. 2003;38 (Suppl 1):206A.
38. Lay CS, Tsai YT, Teg CY, et al. Endoscopic variceal ligation in prophylaxis of first variceal bleeding in cirrhotic patients with high-risk esophageal varices. Hepatology. 1997;25:1346-1350.
39. North Italian Endoscopic Club. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices: a prospective multicenter study. N Engl J Med. 1988;319:983-989.
40. Saab S, DeRosa V, Nieto J, et al. Costs and clinical outcomes of primary prophylaxis of variceal bleeding in patients with hepatic cirrhosis: a decision analytic model. Am J Gastroenterol. 2003;98:763-770.
41. Cales P. Factors associated with failure of propranolol for the prevention of first bleeding in cirrhotic patients. The Study Group of Primary Prophylaxis. Gastroenterol Clin Biol. 1992;16:504-510.
42. Angelica M, Lionetti R. Long-acting nitrates in portal hypertension: to be or not to be? Dig Liver Dis. 2001;33:205-211.
43. Dagradi AE. The natural history of esophageal varices in patients with alcoholic liver cirrhosis: an endoscopic and clinical study. Am J Gastroenterol. 1972;57:520-540.
44. Vorobioff J, Groszmann RJ, Picabea F, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996;111:701-709.
45. Bosh J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol. 2003;38(Suppl):54-68.
46. Hillon P, Lebrec D, Munoz C, et al. Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis. Hepatology. 1982;2:528-531.
47. Garcia-Pagan JC, Escorsell A, Moitinho E, et al. Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. Semin Liver Dis. 1999;19:427-437.
48. De BK, Sen S, Biswas PK, et al. Propranolol in primary and secondary prophylaxis of variceal bleeding among cirrhotics in India: a hemodynamic evaluation. Am J Gastroenterol. 2000;95:2023-2028.
49. Poynard T, Lerrec D, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology. 1987;7:447-451.
50. Villanueva C, Misana J, Balanzo J. Prevention of recurrent variceal bleeding [Letter]. N Engl J Med. 2002;3:209-210.
51. Deleted in proof.
52. Zaman A, Goldberg RJ, Pettit KG, et al. Cost of treating an episode of variceal bleeding in a VA setting. Am J Gastroenterol. 2000;95:1323-1330.
53. Abraczinskas DR, Ookubo R, Grace ND, et al. Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment? Hepatology. 2001;34:1096-1102.
54. Lomas J, Anderson GM, Domnick-Pierre K, et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989;321:1306-1311.
55. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999; 282:1458-1465.
56. Cruz-Correa M, Gross CP, Canto MI, et al. The impact of practice guidelines in the management of Barrett esophagus: a national prospective cohort study of physicians. Arch Intern Med. 2001;161:2588-2595.
57. Ansari M, Shlipak MG, Heidenreich PA, et al. Improving guideline adherence: a randomized trial evaluating strategies to increase B-Blocker use in heart failure. Circulation. 2003;107:2799-2804.
58. Bradley EH, Holmboe ES, Mattera JA, et al. A qualitative study of increasing B-Blocker use after myocardial infarction: why do some hospitals succeed? JAMA. 2001;285:2604-2611.